All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @jmobuilt on TikTok · 14s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @jmobuilt's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Thanks for watching!

@jmobuilt's GLP-1 transformation results, fact-checked

jmobuilt

TikTok creator

62.5K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways. Clinical trials show 14.9% weight loss with semaglutide and 20.9% with tirzepatide over 68-72 weeks when combined with lifestyle interventions. About 25-30% of weight lost is typically lean body mass rather than fat alone.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @jmobuilt's GLP-1 transformation results, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@jmobuilt's GLP-1 transformation results, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@jmobuilt's GLP-1 transformation results, fact-checked" from jmobuilt. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways.

The reason this review is not generic is the source wording and the canonical claim label "glp1 great results gym jmo transformation cut." In this clip, the useful excerpt is: "Thanks for watching!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

SURMOUNT-1 trial found 20.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways. Clinical trials show 14.9% weight loss with semaglutide and 20.9% with tirzepatide over 68-72 weeks when combined with lifestyle interventions. About 25-30% of weight lost is typically lean body mass rather than fat alone.
  • STEP 1 trial showed 14.9% body weight loss with 2.4mg semaglutide over 68 weeks, not rapid transformation
  • SURMOUNT-1 trial found 20.9% weight loss with 15mg tirzepatide, but 74% experienced gastrointestinal side effects

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • STEP 1 trial showed 14.9% body weight loss with 2.4mg semaglutide over 68 weeks, not rapid transformation
  • SURMOUNT-1 trial found 20.9% weight loss with 15mg tirzepatide, but 74% experienced gastrointestinal side effects
  • Resistance training preserves 86% of muscle mass during GLP-1 treatment versus 78% without exercise
  • About 25-30% of total weight lost is lean body mass even with exercise, making some muscle loss inevitable
  • Starting dose is 0.25mg weekly for semaglutide, gradually increased over 16-20 weeks to minimize adverse effects
  • 13% of STEP 1 participants lost less than 5% body weight, showing significant individual variation in results
  • Both medications require 500-calorie deficit diets and 150 minutes weekly exercise for clinical trial results

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

This TikTok shows @jmobuilt's physical transformation with the hashtags suggesting GLP-1 medication use alongside gym training. The creator displays before-and-after photos showing apparent fat loss and muscle definition, tagging it as "great results" from cutting weight.

While the video doesn't make explicit medical claims, the transformation timeline and dramatic results typical of these posts often misrepresent how GLP-1 medications actually work. The "cut" hashtag suggests this is presented as a standard bodybuilding cut rather than medical weight management.

What do clinical trials actually show about GLP-1 results?

The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% body weight loss over 68 weeks with 2.4mg semaglutide. That's about 33 pounds for a 220-pound person, achieved gradually over 16 months.

The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 20.9% weight loss with 15mg tirzepatide over 72 weeks. Both studies required consistent dosing and lifestyle changes including reduced calorie intake and increased physical activity.

What these numbers don't capture is the timeline. Most participants didn't see maximum results until month 12-16, not the rapid transformation often implied by social media posts.

Does combining GLP-1s with resistance training prevent muscle loss?

The STEP 1 trial found that about 25-30% of total weight lost was lean body mass, not just fat. This matches typical patterns seen with any significant weight loss, whether from medication, surgery, or diet alone.

A 2023 study by Hsieh et al. in Obesity found that resistance training during semaglutide treatment preserved more muscle mass compared to medication alone. Participants who lifted weights maintained 86% of their muscle mass versus 78% in the medication-only group.

However, even with exercise, some muscle loss is inevitable during rapid weight loss. The idea that you can cut weight this dramatically while maintaining all muscle mass oversells what's actually possible.

What's misleading about transformation posts like this?

These posts rarely show the full timeline or discuss side effects. The STEP 1 trial reported that 74% of participants experienced gastrointestinal side effects, with 7% discontinuing due to adverse events.

The "great results" framing also ignores individual variation. In STEP 1, while the average was 14.9% weight loss, results ranged from minimal loss to over 25%. About 13% of participants lost less than 5% of their body weight.

Most problematically, these posts present GLP-1 medications as bodybuilding tools rather than diabetes and obesity medications. The dramatic before-and-after format mimics supplement advertising rather than legitimate medical treatment documentation.

What should you actually know about GLP-1 medications?

Semaglutide and tirzepatide work by slowing gastric emptying and affecting appetite regulation through GLP-1 receptors. They're not fat burners or muscle builders. They make you feel full faster and longer.

The medications require lifestyle changes to be effective. Participants in major trials followed 500-calorie deficit diets and exercised 150 minutes per week. The drugs don't work as standalone solutions.

Real results take time and medical supervision. Starting doses are 0.25mg weekly for semaglutide, gradually increased to 2.4mg over 16-20 weeks to minimize side effects. Anyone considering these medications needs proper medical evaluation and ongoing monitoring.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

jmobuilt · TikTok creator

62.5K views on this video

great results #gym #jmo #transformation #cut

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial showed 14.9% body weight loss with 2.4mg?

STEP 1 trial showed 14.9% body weight loss with 2.4mg semaglutide over 68 weeks, not rapid transformation

What does the video say about surmount-1 trial found 20.9% weight loss with 15mg tirzepatide,?

SURMOUNT-1 trial found 20.9% weight loss with 15mg tirzepatide, but 74% experienced gastrointestinal side effects

What does the video say about resistance training preserves 86% of muscle mass during glp-1 treatment?

Resistance training preserves 86% of muscle mass during GLP-1 treatment versus 78% without exercise

What does the video say about about 25-30% of total weight lost?

About 25-30% of total weight lost is lean body mass even with exercise, making some muscle loss inevitable

What does the video say about starting dose?

Starting dose is 0.25mg weekly for semaglutide, gradually increased over 16-20 weeks to minimize adverse effects

What does the video say about 13% of step 1 participants lost less than 5% body?

13% of STEP 1 participants lost less than 5% body weight, showing significant individual variation in results

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by jmobuilt, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.